Literature DB >> 15538223

The membrane proteases adams and hepsin are differentially expressed in renal cell carcinoma. Are they potential tumor markers?

Andreas Roemer1, Lutz Schwettmann, Monika Jung, Carsten Stephan, Jan Roigas, Glen Kristiansen, Stefan A Loening, Ralf Lichtinghagen, Klaus Jung.   

Abstract

PURPOSE: ADAMs (a disintegrin and metalloproteinases) as cell surface proteins with adhesion and protease activity, and hepsin as a transmembrane protease have important roles in many biological processes. We assessed the expression of various ADAMs and of hepsin in human renal cell carcinoma (RCC), and correlated expression with clinicopathological data.
MATERIALS AND METHODS: mRNA expression of ADAM-8, 17, 19, 28, TS1 and TS2, and of hepsin was investigated in paired tissue samples from cancerous and noncancerous parts of the kidneys of 27 patients with RCC who underwent tumor nephrectomy. Measurements were performed by quantitative real-time reverse transcriptase-polymerase chain reaction on a LightCycler instrument (Roche Applied Science, Mannheim, Germany). The data were related to housekeeping gene porphobilinogen deaminase mRNA.
RESULTS: All ADAMs except ADAM-TS1 were significantly higher but hepsin was less expressed (at least p <0.05) in cancerous vs matched noncancerous tissue. Expression was differentially related to tumor stage. ADAM-8 and ADAM-TS2 over expression as well as decreased hepsin expression were associated with shorter patient survival. The Cox proportional hazards regression model revealed that ADAM-TS2 was an independent prognostic factor for cancer related death. ADAM-8 was the best predictor of distant metastases.
CONCLUSIONS: The differential expression of hepsin and ADAMs suggests early and late involvement of membrane proteases in the development of RCC. Their association with the clinical outcome illustrates their potential usefulness as biomarkers for RCC.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15538223     DOI: 10.1097/01.ju.0000144602.01322.49

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  16 in total

1.  The cytosolic domain of protein-tyrosine kinase 7 (PTK7), generated from sequential cleavage by a disintegrin and metalloprotease 17 (ADAM17) and γ-secretase, enhances cell proliferation and migration in colon cancer cells.

Authors:  Hye-Won Na; Won-Sik Shin; Andreas Ludwig; Seung-Taek Lee
Journal:  J Biol Chem       Date:  2012-06-04       Impact factor: 5.157

2.  Detection of early prostate cancer using a hepsin-targeted imaging agent.

Authors:  Kimberly A Kelly; Sunita R Setlur; Robert Ross; Rajesh Anbazhagan; Peter Waterman; Mark A Rubin; Ralph Weissleder
Journal:  Cancer Res       Date:  2008-04-01       Impact factor: 12.701

3.  Overexpression of a disintegrin and metalloprotease 8 in human gliomas is implicated in tumor progression and prognosis.

Authors:  Shiming He; Lianshu Ding; Yizhan Cao; Gang Li; Jianping Deng; Yanyang Tu; Boliang Wang
Journal:  Med Oncol       Date:  2011-10-09       Impact factor: 3.064

4.  Upregulation of a disintegrin and metalloprotease 8 influences tumor metastasis and prognosis in patients with osteosarcoma.

Authors:  Zhehai Li; Qiande Liao; Yuchi Wu; Mingmei Liao; Yuqin Hao; Shengbin Zhang; Shipeng Song; Bing Li; Yang-de Zhang
Journal:  Pathol Oncol Res       Date:  2012-01-05       Impact factor: 3.201

5.  N-glycosylation regulates ADAM8 processing and activation.

Authors:  Srimathi Srinivasan; Mathilde Romagnoli; Andrew Bohm; Gail E Sonenshein
Journal:  J Biol Chem       Date:  2014-10-21       Impact factor: 5.157

6.  ADAM8 expression in prostate cancer is associated with parameters of unfavorable prognosis.

Authors:  Florian R Fritzsche; Monika Jung; Chuanliang Xu; Anja Rabien; Hanka Schicktanz; Carsten Stephan; Manfred Dietel; Klaus Jung; Glen Kristiansen
Journal:  Virchows Arch       Date:  2006-11-08       Impact factor: 4.064

7.  Regulators of gene expression as biomarkers for prostate cancer.

Authors:  Stacey S Willard; Shahriar Koochekpour
Journal:  Am J Cancer Res       Date:  2012-11-20       Impact factor: 6.166

8.  MicroRNA-145 targets the metalloprotease ADAM17 and is suppressed in renal cell carcinoma patients.

Authors:  Kai Doberstein; Nico Steinmeyer; Ann-Kathrin Hartmetz; Wolfgang Eberhardt; Michel Mittelbronn; Patrick N Harter; Eva Juengel; Roman Blaheta; Josef Pfeilschifter; Paul Gutwein
Journal:  Neoplasia       Date:  2013-02       Impact factor: 5.715

9.  ADAM9 is highly expressed in renal cell cancer and is associated with tumour progression.

Authors:  Florian R Fritzsche; Kirsten Wassermann; Monika Jung; Angelika Tölle; Ilka Kristiansen; Michael Lein; Manfred Johannsen; Manfred Dietel; Klaus Jung; Glen Kristiansen
Journal:  BMC Cancer       Date:  2008-06-26       Impact factor: 4.430

10.  ADAM8 expression is associated with increased invasiveness and reduced patient survival in pancreatic cancer.

Authors:  N Valkovskaya; H Kayed; K Felix; D Hartmann; N A Giese; S P Osinsky; H Friess; J Kleeff
Journal:  J Cell Mol Med       Date:  2007 Sep-Oct       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.